Let’s dig into the relative performance of DexCom (NASDAQ:DXCM) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. Patient ...
DexCom (DXCM) exemplifies GARP investing, offering strong growth in glucose monitoring at a price reasonable relative to its industry and supported by robust profitability.
Shares of Eli Lilly and Company (NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require strict fasting or water intake restrictions. The approval, which came months ahead of initial analyst expectations, marks a pivotal
As of April 1, 2026, the global medical technology landscape is undergoing a profound shift, and at the center of this evolution is Medtronic plc (NYSE: MDT). Long regarded as the "sleeping giant" of the healthcare sector, Medtronic has spent the last three years in the throes of a massive structural and cultural overhaul. Today, [...]
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...
What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ...
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea...
While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing.
Some are dealing with declining demand, high costs, or regulatory pressures that could limit future upside.
Date: February 24, 2026 By: Financial Research Analyst Introduction For years, Medtronic plc (NYSE: MDT) was viewed by Wall Street as a reliable but sluggish giant—a "Dividend Aristocrat" that offered safety but lacked the high-octane growth of its specialized med-tech peers. That narrative is shifting rapidly. Today, February 24, 2026, marks a watershed moment for [...]
